Axsome Therapeutics Reports Strong Q2 2025 Earnings with Revenue Growth

Axsome Therapeutics (AXSM) reported Q2 2025 earnings with total product revenues of $150 million, reflecting strong year-over-year and sequential growth driven by Auvelity and Sunosi. The company also announced initial sales for SYMBRAVO and provided insights into gross-to-net discounts for its products.

By Motley Fool Transcribing · Motley Fool · May 4, 2026, 15:15 UTC

Axsome Therapeutics Reports Strong Q2 2025 Earnings with Revenue Growth

Tickers: $AXSM

Topics: financial results pharmaceuticals product sales revenue growth

Read the full article at Motley Fool

More World news

Teekay Tankers Shares Decline Despite Q3 Earnings Beat and New Vessel Orders Seeking Alpha · November 12, 2026, 18:27 UTC
U.S. 30-Year Treasury Auction Yields Rise as Demand Weakens Seeking Alpha · November 12, 2026, 18:30 UTC
Nvidia Names Colette Kress Interim CEO Following Jensen Huang's Resignation Motley Fool · November 12, 2026, 18:26 UTC
Bit Digital Reports Q3 2026 Net Income of $28.5 Million Amid Revenue Decline Motley Fool · November 12, 2026, 18:26 UTC
EZCORP Reports Strong Q4 2026 Results with Significant EBITDA and Revenue Growth Motley Fool · November 12, 2026, 18:16 UTC
Sabre Corp Shares Decline Following Travelport Denial of Merger Speculation Seeking Alpha · November 12, 2026, 18:21 UTC
Lufax Reports Third Quarter 2026 Net Loss Amid Rising Credit Impairment Costs Motley Fool · November 12, 2026, 18:15 UTC
Avantor Reports Return to Organic Revenue Growth in Third Quarter 2026 Motley Fool · November 12, 2026, 18:15 UTC
MGP Ingredients Rebrands to Sempreon and Announces Strategic Shift Toward Ready-to-Drink Products Motley Fool · November 12, 2026, 18:15 UTC
ICON Reports Q3 2026 Revenue of $2 Billion and Accelerating Book-to-Bill Ratio Motley Fool · November 12, 2026, 18:15 UTC